PERSPECTA

News from every angle

← Back to headlines

Ultragenyx Receives FDA IND Clearance for UX016 in GNE Myopathy Treatment

Ultragenyx has announced that its investigational new drug (IND) application for UX016, intended for the treatment of GNE myopathy, has received clearance from the FDA.

30 Mar, 14:38 — 30 Mar, 14:38
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed3h ago

Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy

Read full article →

Related Stories

AI Drone Project Launched to Detect Banana Disease in Davao Region

just now

Biological Impact of Daylight Saving Time on Human Health

22m ago

First Human Case of H9N2 Bird Flu Recorded in Europe

31m ago

Sharks in Caribbean Found to Have Traces of Cocaine, Caffeine, and Painkillers

37m ago